SX-682
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 151 patients (estimated)
- Sponsors
- Syntrix Biosystems, Inc.
- Collaborators
- Moffitt Cancer Center, National Heart, Lung, and Blood Institute (NHLBI), Sidney Kimmel Comprehensive Cancer Center, Winship Cancer Institute, University of Miami, AdventHealth, Mayo Clinic, Montefiore Medical Center
- Tags
- CXCR1 Inhibitor, CXCR2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1574
- NCT Identifier
- NCT04245397
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.